Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair
November 09 2021 - 8:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the research and
discovery of new and effective treatments for psychiatric and
neurological disorders, today announced the formation of its
Scientific Advisory Board (“SAB”) to be chaired by esteemed
psychiatrist, Charles Nemeroff, M.D., Ph.D.
The newly formed SAB will work closely with
Pasithea management to provide direction and support as the Company
advances its mission of developing drugs that target the
pathophysiology underlying psychiatric and neurological
disorders.
“Forming a strong Scientific Advisory Board is
an important step in establishing credibility as we commence our
programs. We are thrilled to welcome Prof. Nemeroff, whose
achievements in psychiatry and neuropsychopharmacology make him an
ideal candidate to lead this important group. We look forward to
his contributions as we begin to build out the rest of the advisory
team, which together with Pasithea’s expert internal leaders and
scientists, will spearhead our research around new molecular
entities, with the goal of bringing novel treatment options for
patients,” said Dr. Tiago Reis Marques, Chief Executive Officer of
Pasithea.
“I am honored to join and chair Pasithea
Therapeutics’ Scientific Advisory Board. There is an urgent need to
find novel approaches to address the growing crisis in mental
health. I am eager to join this talented group of scientists as
they embark on research for new drugs with novel mechanisms of
action to treat psychiatric and neurological disorders,” stated
Prof. Charles Nemeroff.
Prof. Charles B. Nemeroff, M.D., Ph.D., is a
Professor and Chair of the Department of Psychiatry and Behavioral
Sciences at the University of Texas Dell Medical School and Matthew
P. Nemeroff Endowed Chair. His research is focused on the
pathophysiology of mood and anxiety disorders, and he has published
more than 1,100 research reports and reviews. Prof. Nemeroff has
received numerous research and education awards, including the
Kempf Award in Psychobiology, the Samuel Hibbs Award, Research
Mentoring Award, Judson Marmot Award and the Vestermark Award from
the American Psychiatric Association (APA), the Mood Disorders
Award, Bowis Award and Dean Award from the American College of
Psychiatrists (ACP) and the Julius Axelrod Award for mentoring from
the ACNP. He currently sits on the Scientific Advisory Board of the
Brain and Behavioral Research Foundation. Prof. Nemeroff is a
member of the National Academy of Medicine. Prof. Nemeroff received
his medical degree and doctorate at the University of North
Carolina School of Medicine.
About Pasithea Therapeutics
Corp.Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward-Looking StatementsThis
press release contains statements that constitute “forward-looking
statements.” Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the Company.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to the Company on the date of this release. These
forward-looking statements are based upon current estimates and
assumptions and are subject to various risks and uncertainties,
including, without limitation, those set forth in the Risk Factors
section of the Company’s Registration Statement and final
prospectus for the offering filed with the SEC. Thus, actual
results could be materially different. The Company undertakes no
obligation to update these statements whether as a result of new
information, future events or otherwise, after the date of this
release, except as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Sep 2023 to Sep 2024